Skip to main content

The General Approach to Cystic Fibrosis Pulmonary Infection in Greece

  • Chapter
  • 57 Accesses

Part of the book series: Respiratory Pharmacology and Pharmacotherapy ((RPP))

Summary

Cystic Fibrosis is the second most common autosomal recessive genetic disorder in Greece next to Mediterranean Anaemia (thalassaemia). There are about 50–60 affected neonates expected each year. The carrier frequency is estimated at 5% of the general population. There are 287 CF patients attending the CF Centre which was started in 1966 at the Aghia Sophia Children’s Hospital in Athens. 25% of the patients are older than 16 years and the oldest known patient in Greece is 46 years old. From a group of 211 patients regularly followed at the Centre 101 are free from microbial colonization and 110 have positive sputum culture, in 88 of which P. aeruginosa has been cultured. B. cepacia has never been cultured in this series. Therapeutic approach to chest infection consists of oral or IV antibiotics according to the sensitivity of microorganisms cultured in the sputum; home IV therapy is not applied. Some patients are given antibiotics by inhalation and all have intensive physiotherapy. In the majority of patients clinical progress is good: as evaluated by the Shwachman-Kulczycki score 73% are in very good or excellent condition and only 11.8% are in moderate or poor condition. School-age children are attending regular school with low absence rate and good performance. Some of the adult patients are pursuing higher education and the rest are engaged in various professions. Our experience is that the introduction of a programme of aggressive and intensive therapy has had a positive effect on survival and clinical condition and has reduced hospitalization.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The Cystic Fibrosis Genetic Analysis Consortium. Worldwide survey of the OF508 mutation. Amer J Hum Genet 1990; 47: 354–359.

    Google Scholar 

  2. Tsul LC. The spectrum of cystic fibrosis mutations. Trends Genet 1992; 8: 392–398.

    Google Scholar 

  3. Thomasson MJ, Demko CA, Doershuk C. The Cystic Fibrosis. A review of pulmonary infections and interventions. Pediatr Pulmon 1987; 3: 334–351.

    Article  Google Scholar 

  4. Zach MS. Lung disease in cystic fibrosis — an updated concept. Pediatr Pulmon 1990; 8: 188–202.

    Article  CAS  Google Scholar 

  5. Szaff M, Holby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Pediatr Scand 1983; 72: 651–657.

    Article  CAS  Google Scholar 

  6. Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microb Infect Dis 1990; 13: 153–155.

    Article  CAS  Google Scholar 

  7. Hodson M, Penratti A, Batten J. Aerosol carbenican and gentamycin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; 1: 1137–1139.

    Article  Google Scholar 

  8. MacLusky I, Levison H, Goldman R, McLaughlin FJ. Inhaled antibiotics in cystic fibrosis: Is there a therapeutic effect? J M Pediatr 1986; 108: 861–865.

    Article  CAS  Google Scholar 

  9. Hodson ME. Aerosol antibiotic therapy. Pediatr Pulmonol 1991: 6 (Suppl): 76–78.

    Google Scholar 

  10. Desmond KJ, Schwenk WF, Thomas E, Bewdry PH, Coates AL. Immediate and long term effects of chest physiotherapy in patients with cystic fibrosis. J of Pediatr (1983) 103: 538–542.

    Article  CAS  Google Scholar 

  11. Moams MB, Hunt GH, Rushworth R. Bacterial flora of the respiratory tract in patients with cystic fibrosis 1950–1971. Arch Dis Child 1972; 47: 902–907.

    Article  Google Scholar 

  12. Hoiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Ped Scand 1982; suppl 301: 33–54.

    Google Scholar 

  13. Marks MI. The pathogenesis and treatment of pulmonary infection in patients with cystic fibrosis. J M Pediatr 1981: 98: 172–179.

    Google Scholar 

  14. Wood RE. Treatment of CF lung disease in the first two years. Pediatr Pulmon 1989; 4 suppl: 68–70.

    Google Scholar 

  15. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than bronchodilators and chest physiotherapy alone. Amer Rev Respir Dis 1990; 141: 914–921.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Birkhäuser Verlag, Basel/Switzerland

About this chapter

Cite this chapter

Adam, G.S. (1996). The General Approach to Cystic Fibrosis Pulmonary Infection in Greece. In: Bauernfeind, A., Marks, M.I., Strandvik, B. (eds) Cystic Fibrosis Pulmonary Infections: Lessons from Around the World. Respiratory Pharmacology and Pharmacotherapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7359-8_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7359-8_16

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-0348-7361-1

  • Online ISBN: 978-3-0348-7359-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics